Table 1.
Demographic characters of patients in RATS group and VATS group before and after 1:1 propensity score matching
| Characteristics | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| RATS group (n = 85) | VATS group (n = 95) | P Value | RATS group (n = 66) | VATS group (n = 66) | P Value | |
| Age (years) | 51.67 ± 13.07 | 52.67 ± 10.42 | 0.573 | 52.95 ± 12.09 | 51.88 ± 10.42 | 0.585 |
| Gender | 0.036 | 0.384 | ||||
| Male | 49 (57.65) | 41 (43.16) | 31 (46.97) | 36 (54.55) | ||
| Female | 36 (42.35) | 54 (56.84) | 35 (53.03) | 30 (45.45) | ||
| BMI (Kg/m2) | 23.32 ± 2.73 | 23.53 ± 3.28 | 0.632 | 23.53 ± 2.57 | 23.64 ± 3.36 | 0.839 |
| Smoking history | 0.481 | 0.455 | ||||
| Yes | 32 (37.65) | 31 (32.63) | 19 (28.79) | 23 (34.85) | ||
| No | 53 (62.35) | 64 (67.37) | 47 (71.21) | 43 (65.15) | ||
| Comorbidity (%) | 0.883 | 0.966 | ||||
| Hypertension | 13 (15.29) | 23 (24.21) | 11 (16.67) | 13 (19.70) | ||
| Diabetes | 3 (3.53) | 5 (5.26) | 3 (4.55) | 3 (4.55) | ||
| Coronary heart disease | 4 (4.71) | 6 (6.32) | 3 (4.55) | 2 (3.03) | ||
| COPD | 2 (2.35) | 1 (1.05) | 1 (1.52) | 1 (1.52) | ||
| Others | 8 (9.41) | 11 (11.58) | 4 (6.06) | 6 (9.09) | ||
| Myasthenia Gravis, n (%) | 27 (31.76) | 31 (32.63) | 0.901 | 19 (28.79) | 16 (24.24) | 0.554 |
| Tumor size (cm), median (IQR) | 4.8 (3.7, 6.5) | 4.0 (2.8, 5.5) | 0.001 | 4.6 (3.5, 5.6) | 4.6 (3.5, 5.9) | 0.689 |
| Pre-operative treatment, n (%) | 1.000 | 1.000 | ||||
| Yes | 1 (1.18) | 1 (1.05) | 1 (1.52) | 1 (1.52) | ||
| No | 84 (98.82) | 94 (98.95) | 65 (98.48) | 65 (98.48) | ||
| WHO Classification, n (%) | 0.524 | 0.865 | ||||
| A | 16 (18.82) | 14 (14.74) | 10 (15.15) | 9 (13.64) | ||
| AB | 21 (24.71) | 24 (25.26) | 18 (27.27) | 19 (28.79) | ||
| B1 | 8 (9.41) | 17 (17.89) | 8 (12.12) | 8 (12.12) | ||
| B2 | 21 (24.71) | 24 (25.26) | 15 (22.73) | 19 (28.79) | ||
| B3 | 8 (9.41) | 9 (9.47) | 8 (12.12) | 4 (6.05) | ||
| Thymic carcinoma | 11 (12.94) | 7 (7.38) | 7 (10.61) | 7 (10.61) | ||
| Masaoka Stage, n (%) | 0.200 | 0.655 | ||||
| I | 48 (56.47) | 60 (63.16) | 38 (57.58) | 39 (59.09) | ||
| IIa | 23 (27.06) | 15 (15.79) | 17 (25.76) | 11 (16.67) | ||
| IIb | 6 (7.06) | 14 (14.74) | 6 (9.09) | 10 (15.16) | ||
| III | 5 (5.88) | 4 (4.21) | 3 (4.54) | 4 (6.05) | ||
| IV | 3 (3.53) | 2 (2.10) | 2 (3.03) | 2 (3.03) | ||
| Adjuvant treatment, n (%) | 15 (17.65) | 18 (18.95) | 0.482 | 11 (16.67) | 12 (18.18) | 0.783 |
| Chemotherapy | 12 (14.12) | 8 (8.42) | 8 (12.12) | 6 (9.09) | ||
| Radiation Therapy | 12 (14.12) | 16 (16.84) | 9 (13.64) | 11 (16.67) | ||
Abbreviations IQR Interquartile range, RATS Robot-assisted thoracoscopic surgery, VATS video-assisted thoracoscopic surgery, COPD Chronic obstructive pulmonary disease, BMI Body mass index